Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Fig. 3

Analysis of RTK activation. a An example phospho-RTK antibody array showing the location of relevant RTKs within the array. b Phospho-RTK arrays developed using lysates from ZR-75-30, BT474 and AU565 cells treated with either trastuzumab (100 nM, 4 h) or pertuzumab (100 nM, 4 h). c AU565 and BT474 cells were treated with pertuzumab (100 nM) for the time points indicated. Western blotting was performed with lysates from these cells with the total and phospho-RTK antibodies indicated. Data is presented as a heat map showing the relative changes in phosphorylation (n = 3, mean), raw data and statistical analysis is presented in Additional file 2: Figure S4

Back to article page